💩 Could a familiar GI biomarker help predict which patients with immune checkpoint inhibitor colitis won't respond to corticosteroids? 💊🔮 This research in @FrontGastro_BMJ examines faecal calprotectin as a predictor of corticosteroid non-responsiveness in patients with immune checkpoint inhibitor colitis. 🔬📊 Identifying non-response earlier could help inform treatment decisions in this increasingly important complication of cancer immunotherapy. 🎯🩺 Explore the findings here 👇 fg.bmj.com/content/early/202… #Immunotherapy #Colitis #FaecalCalprotectin #CancerTreatment #Gastroenterology #Oncology #MedicalResearch #GITwitter @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

💩 Could a stool test predict steroid failure in ICI colitis? Immune checkpoint inhibitor (ICI) colitis can be difficult to manage, with up to one-third of patients requiring escalation beyond corticosteroids. This study found: 📈 Faecal calprotectin predicted steroid non-response 🎯 A threshold of >620 μg/g identified patients more likely to require infliximab or vedolizumab 🔬 Endoscopic severity and histology were not predictive in this cohort 🔗 fg.bmj.com/content/early/202… #FrontlineGastroenterology #IBD #Oncology #Immunotherapy #Calprotectin #MedEd @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy

Acute severe UC: can early markers predict who responds to second-line therapy? 🚨🩺 The RESCUE-ASC study in @FrontGastro_BMJ shows how endoscopic severity and C-reactive protein can help predict initial and 12-month outcomes after rescue medical therapy in acute severe ulcerative colitis. 📊🔎 Essential reading for IBD teams managing high-stakes inpatient UC decisions. Read more: fg.bmj.com/content/early/202… #AcuteSevereUC #UlcerativeColitis #IBD #CRP #Endoscopy #FrontlineGastro #GItwitter #InflammatoryBowelDisease #IBDTreatment #ClinicalResearch @drkrpradeep @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

Subcutaneous infliximab monotherapy in IBD: does it persist in the real world? 💉📊 In @FrontGastro_BMJ, this real-world study examines treatment persistence and efficacy of subcutaneous infliximab monotherapy in patients with inflammatory bowel disease. 🧑‍⚕️🔬 Important data as IBD services consider convenience, adherence, drug levels and long-term treatment strategy. Read more: fg.bmj.com/content/early/202… #IBD #Infliximab #SubcutaneousInfliximab #CrohnsDisease #UlcerativeColitis #FrontlineGastro #GItwitter #InflammatoryBowelDisease #IBDTreatment #ClinicalResearch @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

S/C IFX - A REAL WORLD EXPERIENCE ⭐ Original research - check out this retrospective observational cohort study! ⭐ 🧍 101 adult patients on SC-IFX monotherapy - 57 (56.4%) CD, 44 (43.6%) UC 💉 Treatment persistence at 12 months was 91.1% (92/101) with maintenance or improvement of clinical, biochemical and endoscopic outcomes at 12 months 📉 Multivariate regression analysis identified prior ileal resection as an independent predictor of treatment discontinuation at 12 months Check out the full paper here!! 👇 👇 👇 fg.bmj.com/content/early/202… @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @JonnyBlackwell @alenkabrooks @DCharabaty @jennie_clough @rachelcooney7 @DisneyBen @bealoquebea @jklimdi @wingyanjoyce @Jonathansegal85 #IBD #IBDTwitter #IBDAwareness #myIBD #IBDChat #inflammatoryboweldisease

💥 ASUC rescue therapy just got predictable. Second-line medical rescue therapy responders can be identified early with: 🔹 UCEIS <6 🔹 CRP <22 mg/L on day 3 Near-zero colectomy risk in both cohorts. 🔓 Read the RESCUE-ASC study: fg.bmj.com/content/early/202… Led by @drkrpradeep #IBD #FGjournal #FGoriginalresearch #MedTwitter @CrohnsColitisUK @BritSocGastro @Y_ECCO_IBD @my_ueg @CrohnsColitisFn @CrohnsColitisR @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

🩸@FrontGastro_BMJ: Patients with IBD have a 57% increased risk of venous thromboembolism (VTE) within 30 days post-discharge (OR 1.57). 🛌 Risk after non-surgical admissions even higher (OR 1.70). 💉Should extended thromboprophylaxis be routine for our IBD patients? 👉 fg.bmj.com/content/early/202…